{"id":"W4296202942","doi":"10.1016/j.jtocrr.2022.100408","title":"A Phase 1, Open-Label, Dose-Escalation Study of L-DOS47 in Combination With Pemetrexed Plus Carboplatin in Patients With Stage IV Recurrent or Metastatic Nonsquamous NSCLC","year":2022,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Helix Biopharma (Canada)","funders":"","keywords":"Medicine; Carboplatin; Tolerability; Pemetrexed; Rash; Internal medicine; Adverse effect; Neutropenia; Febrile neutropenia; Dosing; Loading dose; Oncology; Gastroenterology; Pharmacology; Urology; Toxicity; Chemotherapy; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000907114,0.001359674,0.002042465,0.0004586595,0.0003581511,0.0008510306,0.0008171459,0.0009858828,0.002383629],"category_scores_gemma":[0.000649329,0.0006383391,0.001126752,0.0003512857,0.0009470735,0.0008061512,0.0002956367,0.002529136,0.0005848241],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008105448,"about_ca_system_score_gemma":0.001245966,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007716395,"about_ca_topic_score_gemma":0.002179094,"domain_scores_codex":[0.9996878,0.0001313827,0.00001730237,0.00006915935,0.00003599754,0.00005836306],"domain_scores_gemma":[0.9995448,0.00007144186,0.0001204379,0.0000461412,0.0000318077,0.0001853114],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.534964,0.1543253,0.008094112,0.001920233,0.002339969,0.0004040949,0.0009294914,0.005429683,0.1535902,0.0003215992,0.00346549,0.1342159],"study_design_scores_gemma":[0.2899557,0.6874359,0.01159534,0.00003830954,0.00041248,0.0002286674,0.00009334132,0.00126283,0.006776202,0.0001277968,0.002036483,0.00003701639],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9965874,0.0009112269,0.0003102917,0.0001454116,0.00005676975,0.001021454,0.000287441,0.00005215201,0.0006278591],"genre_scores_gemma":[0.993674,0.001171209,0.001061729,0.0003450233,0.00008646024,0.001067872,0.0008625411,0.00002132723,0.001709755],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002383629,"threshold_uncertainty_score":0.007974029,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2669794915815009,"score_gpt":0.5310140040131872,"score_spread":0.2640345124316864,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}